Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 9/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.42 |
| ▸ | MPL | P40238 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 3/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1924539 | 0.91 | NOTUM (0.36) | MPLKIF11MAPK14MAPK13MAPK12 | |
| SCHEMBL1924673 | 0.88 | S1PR1 (0.36) | CYP11B2CYP11B1MAPK14MAPK13MAPK12 | |
| SCHEMBL1924861 | 0.86 | KDR (0.40) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL1926709 | 0.86 | S1PR1 (0.46) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL1923886 | 0.85 | CTSS (0.37) | MAPK14GRM2KDM4EALDH1A1 | |
| SCHEMBL1924870 | 0.85 | KIF11 (0.44) | KIF11MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1925301 | 0.83 | CTSS (0.41) | GRM2KDM4EALDH1A1 | |
| SCHEMBL1925037 | 0.83 | AAK1 (0.44) | MAPK14 | |
| SCHEMBL1924113 | 0.83 | PSD (0.47) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL1925218 | 0.82 | NPC1 (0.44) | MAPK14MAPK13MAPK12MAPK11KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670801-B1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| US-7514443-B2 | Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of metabotropic glutamate receptors | HOFFMANN-LA ROCHE INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080051421-A1 | Pyrazolo-pyridine | WICHMANN JUERGEN | 2008-02-28 | — | — | US | disclosed |
| US-7329662-B2 | Pyrazolo-pyridine | HOFFMANN-LA ROCHE INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20050130992-A1 | Pyrazolo-pyridine | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130992-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | CYP11B2 97/4885CYP11B1 107/4885MPL 792/4885 |
| US-20080051421-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | CYP11B2 97/4885CYP11B1 107/4885MPL 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.